Gulliver

Gulliver Biomed is dedicated to advancing the field of single domain antibodies (sdAbs), commonly known as NANOBODY® antibodies or VHHs. These unique antibodies offer significant advantages in biomedicine, bioengineering, diagnostics, and personalized medicine, including applications such as CAR-T therapy. Their smaller size—approximately one-tenth that of conventional IgG antibodies—facilitates bioengineering and custom adaptation. Additionally, the availability of their cDNA and protein sequences enhances reproducibility, addressing common challenges associated with traditional antibodies. We specialize in developing a comprehensive nanobody portfolio and generating custom nanobodies tailored to the specific needs of the research community and private industry. Our services provide sophisticated biological tools for biomedical, biochemical, biophysical, pharmaceutical, and cell biological research. By offering these versatile antibodies, we aim to inspire new applications and support the advancement of scientific work. Our mission is to foster single domain antibody research and make these powerful tools accessible to private enterprises and the broader scientific community. We are committed to delivering high-quality, custom-tailored nanobody solutions that meet the diverse needs of our clients, empowering them to stay at the forefront of research and innovation.